LINC00968 can inhibit the progression of lung adenocarcinoma through the miR-21-5p/SMAD7 signal axis

Author:

Zhu Yuxing1,Bo Hao12,Chen Zhizhao13,Li Jingjing13,He Dong4,Xiao Mengqing1,Xiang Liang1,Jin Long1,Zhou Jianda5,Gong Lian1,Zhou Yanhong6,Zhou Ming6,Xiong Wei6,Xing Xiaowei7,Li Ruhong8,Cao Ke1

Affiliation:

1. Department of Oncology, Third Xiangya Hospital of Central South University, Changsha 410013, China

2. Department of Plastic Surgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China

3. Institute of Reproductive and Stem Cell Engineering, Central South University, Changsha 410083, Hunan, China

4. Department of Respiration, The Second People’s Hospital of Hunan Province of Hunan University of Chinese Medicine, Changsha 410000, China

5. Department of Plastic Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China

6. Cancer Research Institute and Key Laboratory of Carcinogenesis of Ministry of Health, Central South University, Changsha 410078, China

7. Center for Medical Experiments, Third Xiangya Hospital, Central South University, Changsha 410013, China

8. Yan’an Affiliated Hospital of Kunming Medical University, Kunming 650051, China

Publisher

Impact Journals, LLC

Subject

Cell Biology,Aging

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3